Researcher
Yanina Jansen
- Keywords:Medicine
- Disciplines:Other translational sciences not elsewhere classified, Other clinical sciences not elsewhere classified, Other basic sciences not elsewhere classified
Affiliations
- Laboratory for Medical and Molecular Oncology (Research group)
Member
From22 Mar 2021 → 23 Jun 2021 - Surgery (Department)
Member
From1 Feb 2020 → 31 Jan 2022 - Surgery (Department)
Member
From1 Aug 2017 → 31 Jan 2022 - Faculty of Medicine and Pharmacy (Faculty)
Member
From6 Oct 2016 → 19 Sep 2021 - Faculty of Medicine and Pharmacy (Faculty)
Member
From16 Oct 2015 → 23 Jun 2021 - Clinical sciences (Department)
Member
From1 Jan 2014 → 31 Jul 2017 - Immunology and Microbiology (Department)
Member
From15 Nov 2013 → 31 Dec 2013 - Medical Oncology (Department)
Member
From1 Oct 2013 → 31 Jul 2017 - Faculty of Medicine and Pharmacy (Faculty)
Member
From12 Sep 2012 → 10 Sep 2015 - Surgery (Department)
Member
From1 Aug 2012 → 31 Jul 2013 - Faculty of Medicine and Pharmacy (Faculty)
Member
From1 Sep 2008 → 29 Jun 2012
Publications
1 - 10 of 10
- Intestinal ischemia in COVID-19 patients : a case series(2023)
Authors: Tobias Kristiaan Van De Winkel, Nouredin Messaoudi, Martijn Schoneveld, Ellen Van Eetvelde, Yanina Jansen
Pages: 1-8 - Timing of surgery following SARS‐CoV‐2 infection: an international prospective cohort study(2021)
Authors: Yanina Jansen, Michaël Jean-Marie Ruyssers, Marc Duinslaeger
Pages: 748-758 - Whole-Body MRI for the Detection of Recurrence in Melanoma Patients at High Risk of Relapse(2021)
Authors: Yanina Jansen, Inneke Willekens, Teofila Seremet, Gil Awada, Julia Katharina Schwarze, Johan De Mey, Carola Brussaard, Bart Neyns
Pages: 1-13 - A Comprehensive Analysis of Baseline Clinical Characteristics and Biomarkers Associated with Outcome in Advanced Melanoma Patients Treated with Pembrolizumab(2021)
Authors: Gil Awada, Yanina Jansen, Julia Katharina Schwarze, Jens Tijtgat, Lennert Hellinckx, Odrade Gondry, Sim Vermeulen, Sarah Warren, Kelly A Schats, Pieter-Jan van Dam, et al.
Pages: 1-18 - A randomized controlled phase II clinical trial on mRNA electroporated autologous monocyte-derived dendritic cells (TriMixDC-MEL) as adjuvant treatment for stage III/IV melanoma patients who are disease-free following the resection of macrometastases(2020)
Authors: Yanina Jansen, Vibeke Kruse, Jurgen Corthals, Kelly A Schats, Pieter-Jan van Dam, Teofila Seremet, Carlo Heirman, Lieve Brochez, Mark Kockx, Kris Thielemans, et al.
Pages: 2589-2598 - Illustrative cases for monitoring by quantitative analysis of BRAF/NRAS ctDNA mutations in liquid biopsies of metastatic melanoma patients who gained clinical benefits from anti-PD1 antibody therapy(2018)
Authors: Teofila Seremet, Simon Planken, Max Schreuer, Yanina Jansen, Mélanie Delaunoy, Hakim El Housni, Danielle Lienard, Véronique Del Marmol, Pierre Heimann, Bart Neyns
Pages: 65-70 - Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAF(V600)-mutant melanoma(2017)
Authors: Max Schreuer, Yanina Jansen, Simon Planken, Ines Chevolet, Teofila Seremet, Vibeke Krüse, Bart Neyns
Pages: 464-472 - SARS-CoV-2 infection and venous thromboembolism after surgery: an international prospective cohort study
Authors: Marc Duinslaeger, Yanina Jansen, Michaël Jean-Marie Ruyssers
Pages: 28-39 - Pembrolizumab for the treatment of uveal melanoma
Authors: Yanina Jansen, Teofila Seremet, Bart Neyns
- The role of local therapy in the treatment of solitary melanoma progression on immune checkpoint inhibition
Authors: Judith M Versluis, Anne M Hendriks, Alison M Weppler, Lauren J Brown, Karlijn de Joode, Karijn P M Suijkerbuijk, Lisa Zimmer, Ellen W Kapiteijn, Clara Allayous, Douglas B Johnson, et al.
Pages: 72-83